Search

Displaying results 3421 - 3430 of 3735 in total
  1. Drug

    Opelconazole

    go.drugbank.com/drugs/DB18251
    Investigational

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP3A Inducers
  2. Drug

    CC-90001

    go.drugbank.com/drugs/DB18445
    Investigational

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  3. Drug

    APPD

    go.drugbank.com/drugs/DB18603
    Experimental

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  4. Drug

    P-42 peptide

    go.drugbank.com/drugs/DB18610
    Experimental

    P-42 peptide is a synthetic 23 amino acid peptide AASSGVSTPGSAGHDIITEQPRS derived from the Huntingtin protein

  5. Drug

    Enavogliflozin

    go.drugbank.com/drugs/DB18970
    Investigational

    Enavogliflozin is under investigation in clinical trial NCT06399835 (Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  6. Drug

    Aminoflavone

    go.drugbank.com/drugs/DB19077
    Investigational

    Aminoflavone is under investigation in clinical trial NCT01015521 (Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  7. Drug

    Arketamine

    go.drugbank.com/drugs/DB19150
    Investigational

    Arketamine is under investigation in clinical trial NCT05414422 (A Randomized, Placebo-controlled, Double-blind Study to Assess Safety and Efficacy of PCN-101 in TRD).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Substrates
  8. Drug

    Substance P

    go.drugbank.com/drugs/DB19198
    Investigational

    Substance P is under investigation in clinical trial NCT03738878 (Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1).

    Categories: Substance P, antagonists & inhibitorsSynonyms: Substance P, Neurokinin p
  9. Drug

    Camizestrant

    go.drugbank.com/drugs/DB19218
    ApprovedInvestigational

    Camizestrant is an oral selective estrogen receptor degrader (SERD) and estrogen receptor (ER) antagonist used in combination with a CDK4/6 inhibitor to treat hormone receptor-positive, HER2-negative locally … [L64094,L64107] It binds the ligand binding domain of ERα, antagonizing ERα encoded by both wild-type and mutated *ESR1* and inducing proteasome-dependent degradation of the receptor without agonizing

    Categories: Estrogen Receptor Antagonists, Selective Estrogen Receptor Degraders
  10. Drug

    Peginterferon alfa-2a

    go.drugbank.com/drugs/DB00008
    ApprovedInvestigational

    Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway.

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors